Literature DB >> 3841366

The pharmacokinetics of alpha-methyldopa in dogs.

G M Kochak, W D Mason.   

Abstract

alpha-Methyldopa was intraarterially and orally administered to dogs at two dose levels in a randomized complete crossover design. The appearance of secondary peaks in the plasma concentration-time profiles indicated the presence of enterohepatically recycled methyldopa. This was established by the absence of a secondary peak following readministration of a dose after biliary cannulation and the detection of methyldopa in the bile of a cannulated dog. Enterohepatic recirculation was estimated to account for a mean of 16.2% of the area under the plasma concentration-time profile after intraarterial administration. Total systemic clearance, defined as the sum of elimination by all routes from the general circulation of the administered dose, and corrected for enterohepatic recirculation, averaged (+/- SD) 99.4 +/- 24.6 ml/min in the dog. An extended average apparent terminal half-life of 6.0 +/- 5.2 hr was exhibited after oral administration compared to an average half-life of 3.1 +/- 1.8 hr following intraarterial administration. Elimination kinetics were linear in the dose range studied. Oral plasma concentration data suggest that the apparent bioavailable fraction may be dose dependent.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3841366     DOI: 10.1007/bf01061477

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  31 in total

Review 1.  Actions of gastrointestinal hormones and related peptides on the motor function of the biliary tract.

Authors:  T M Lin
Journal:  Gastroenterology       Date:  1975-10       Impact factor: 22.682

2.  THE METABOLISM OF METHYLDOPA IN HYPERTENSIVE HUMAN SUBJECTS.

Authors:  R P BUHS; J L BECK; O C SPETH; J L SMITH; N R TRENNER; P J CANNON; J H LARAGH
Journal:  J Pharmacol Exp Ther       Date:  1964-02       Impact factor: 4.030

3.  STUDIES ON THE METABOLISM AND MECHANISM OF ACTION OF METHYLDOPA.

Authors:  A SJOERDSMA; A VENDSALU; K ENGELMAN
Journal:  Circulation       Date:  1963-10       Impact factor: 29.690

4.  Plasma turnover of methyldopa in advanced renal failure.

Authors:  E Myhre; E K Brodwall; O Stenbaek; T Hansen
Journal:  Acta Med Scand       Date:  1972-04

5.  The effect of methyldopa on renal function in patients with renal insufficiency.

Authors:  E K Brodwall; E Myhre; O Stenbaek; T Hansen
Journal:  Acta Med Scand       Date:  1972-04

6.  The renal excretion of methyldopa.

Authors:  E Myhre; E K Brodwall; O Stenbaek; T Hansen
Journal:  Scand J Clin Lab Invest       Date:  1972-04       Impact factor: 1.713

7.  Pharmacokinetics of methyldopa in man.

Authors:  K C Kwan; E L Foltz; G O Breault; J E Baer; J A Totaro
Journal:  J Pharmacol Exp Ther       Date:  1976-08       Impact factor: 4.030

8.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

9.  Combined clinical and metabolic study of the effects of alpha-methyldopa on hypertensive patients.

Authors:  L F Prescott; R P Buhs; J O Beattie; O C Speth; N R Trenner; L Lasagna
Journal:  Circulation       Date:  1966-08       Impact factor: 29.690

10.  The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects.

Authors:  W Y Au; L G Dring; D G Grahame-Smith; P Isaac; R T Williams
Journal:  Biochem J       Date:  1972-08       Impact factor: 3.857

View more
  3 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  A new method to estimate parameters of pharmacokinetics with enterohepatic circulation.

Authors:  F Abi Khalil; M Hanocq; J Dubois
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

Review 3.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.